Department of Medicine.
Clin Med Insights Oncol. 2010 Nov 16;4:117-25. doi: 10.4137/CMO.S6161.
Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 4 × 10(6) units of IFN-α and 125 μg/m(2) of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seven others were taken off study due to flu-like symptoms and/or increase in liver enzymes. With a median follow-up of 45.5 months, the median overall survival was not reached while the median progression-free survival was 28 months. Eleven patients (42%) have remained in very good partial remission or complete remission since ASCT. In conclusion, our results demonstrate that maintenance with GM-CSF and IFN-α is safe and effective.
干扰素 α（IFN-α）已被用于多发性骨髓瘤（MM）患者自体干细胞移植（ASCT）后的维持治疗。在这项研究中，我们将 GM-CSF 与 IFN-α 联合使用，以提高 ASCT 后骨髓瘤患者对 IFN 的耐受性。主要目的是评估这种维持治疗的骨髓抑制毒性和疗效。治疗包括每周三次给予 4×10(6)单位 IFN-α 和 125 μg/m(2)的 GM-CSF，持续 12 个月。27 例患者在 ASCT 后 120 天内入组。1 例患者因血小板减少而停止治疗，另外 7 例因流感样症状和/或肝酶升高而退出研究。中位随访 45.5 个月时，中位总生存期尚未达到，中位无进展生存期为 28 个月。11 例患者（42%）自 ASCT 以来一直处于非常好的部分缓解或完全缓解状态。总之，我们的结果表明，GM-CSF 和 IFN-α 的维持治疗是安全有效的。
